Asset Details
Do you wish to reserve the book?
Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan
Do you wish to request the book?
Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan
2025
Overview
Catechol-O-methyltransferase (COMT) inhibitors are used to alleviate motor fluctuations, such as wearing-off, in people with Parkinson’s disease (PwPD). Opicapone, a COMT inhibitor has long-lasting efficacy when administered once daily, but there is limited real-world clinical data in Japanese participants. This study aimed to evaluate the one-year continuation rate of opicapone in Japanese PwPD in real-world clinical practice and to identify factors influencing this continuation rate.
This retrospective study analyzed data from 58 Japanese PwPD treated with opicapone at the Department of Neurology, Fukuoka University Hospital. We compared patients who continued opicapone for one year with those who discontinued it and examined factors influencing the continuation rate.
Among the 58 PwPD, 26 (44.8%) continued opicapone for one year. Binomial logistic regression analysis identified male sex (odds ratio: 0.223, 95 % confidence interval: 0.056-0.878) and switching from entacapone (odds ratio: 0.215, 95 % confidence interval: 0.056-0.825) as significant factors influencing the one-year continuation rate.
Switching to opicapone in patients with suboptimal responses to entacapone may enhance the continuation rate.
•One-year continuation rate of opicapone in Japanese patients with Parkinson's disease was 44.8 %.•Patients of male sex and those who switched from entacapone had higher continuation rates of opicapone.•Poor efficacy was the most common reason for opicapone discontinuation.•Adverse events, including dyskinesia and hallucinations, occurred mostly within the first three months of starting opicapone.•Opicapone may improve motor symptoms in patients inadequately controlled with entacapone.
Publisher
Elsevier B.V,Elsevier Limited
Subject
/ Antiparkinson Agents - therapeutic use
/ Catechol O-methyltransferase
/ Catechol O-Methyltransferase Inhibitors - administration & dosage
/ Catechol O-Methyltransferase Inhibitors - therapeutic use
/ Female
/ Humans
/ Japan
/ Male
/ Oxadiazoles - administration & dosage
/ Oxadiazoles - therapeutic use
/ Parkinson Disease - drug therapy
/ Patients
